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Acute effects of electronic and tobacco cigarettes on
vascular and respiratory function in healthy
volunteers: a cross-over study
Danie`le M.I. Kerra, Katriona J.M. Brooksbanka, Richard G. Taylorb, Karine Pinela, Francisco J. Riosa,
Rhian M. Touyza, and Christian Dellesa
Objectives : To assess the acute effects of nicotine-
containing electronic cigarettes versus tobacco smoking on
vascular and respiratory function and circulating
microparticles, particularly platelet microparticles (PMPs,
biomarker of haemostasis/thrombosis) and endothelial
microparticles (EMPs, biomarker of endothelial function).
Methods : Heart rate (HR), blood pressure, reactive
hyperaemia index (RHI, microvascular reactivity),
augmentation index (arterial stiffness) and respiratory
function were assessed in 20 smokers immediately before
and after electronic cigarettes use and tobacco smoking.
The number of microparticles was determined by flow
cytometry using counting beads as a reference. Labelling
with Annexin-V was used to detect the total microparticle
fraction. EMPs were characterized as CD31RCD42 and
PMPs as CD31RCD42R.
Results : HR increased after electronic cigarettes use and
tobacco smoking (P<0.001), whereas blood pressure
remained unchanged (P>0.05). RHI (P¼ 0.006),
augmentation index (P¼0.010) but not augmentation
index standardized to HR 75bpm (P>0.05) increased with
electronic cigarettes use but not with tobacco smoking.
Following tobacco smoking, there was a significant
increase in total microparticles (P<0.001), EMPs
(P<0.001) and PMPs (P<0.001). In contrast, electronic
cigarettes were only associated with an increase in PMPs
(P<0.001), with no significant changes in the total
microparticle fraction or EMPs (all P> 0.05). Peak
expiratory flow significantly decreased following electronic
cigarettes use (P¼0.019).
Conclusion : Our results demonstrate that acute exposure
to tobacco smoking as well as electronic cigarettes
influences vascular and respiratory function. Where
tobacco smoking significantly increased microparticle
formation, indicative of possible endothelial injury,
electronic cigarettes use induced vasoreactivity and
decreased peak expiratory flow. These findings suggest
that both electronic cigarettes and tobacco smoking
negatively impact vascular function.
Keywords: electronic cigarettes, endothelial function,
microparticles, peripheral arterial tonometry, respiratory
function, tobacco cigarettes, vascular function
Abbreviations: AI@75, augmentation index at heart rate
of 75 bpm; COSSH, control of substances hazardous to
health; EMP, endothelial microparticle; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; GC/
MS, gas chromatography/mass spectrometry; GC–NDP,
gas chromatography with a nitrogen–phosphorous
detector; NicoTAR, Nicotine and Tobacco Product
Assessment Shared Resource; NRT, nicotine replacement
therapy; PAT, peripheral arterial tonometry; PECAM-1,
platelet endothelial cell adhesion molecule; PEF, peak
expiratory flow; PFP, platelet free plasma; PMP, platelet
microparticle; PWA, pulse wave amplitude; RCF, relative
centrifugal force; RHI, reactive hyperaemia index; SD,
standard deviation; SDC, supplemental digital content; sE-
selectin, endothelial leukocyte adhesion molecule-1;
sICAM-1, soluble intercellular adhesion molecule 1; sP-
selectin, soluble platelet selectin; sVCAM-1, soluble
vascular adhesion molecule 1
INTRODUCTION
I
n the United Kingdom, tobacco smoking accounts
for approximately 122 000 deaths per annum of
which 70% are secondary to lung cancer, chronic
obstructive pulmonary disease or vascular disease [1].
Despite tobacco smoking being entirely preventable and
a modifiable risk factor, 9.4 million people in the United
Kingdom continue to smoke [2]. This is because the desire
to compulsively smoke is primarily related to nicotine
addiction; however, the sensorimotor cues and behavioural
rituals associated with tobacco smoking should not be
underestimated [3,4].
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Tobacco harm reduction strategies in relation to smoking
cessation have focused upon delivering nicotine without
the products of combustion. Since 2011, the use of elec-
tronic cigarettes as a smoking cessation aid has gained
unprecedented popularity. Electronic cigarette use has
replaced medicinal nicotine replacement therapy (NRT)
as the preferred nicotine replacement product to support
quit attempts [5]. Electronic cigarettes are hand-held devices
that deliver nicotine via the oral inhalation route. An aero-
sol, which is commonly referred to as vapour is produced
and inhaled by heating a liquid (e-liquid) commonly com-
posed of a mixture of water, propylene glycol, vegetable
glycerine, flavourings and nicotine. Unlike conventional
NRT, electronic cigarettes are capable of emulating both the
physicality and modality of nicotine delivery associated
with tobacco smoking. Importantly, the use of electronic
cigarettes is not associated with the products of combus-
tion, which are accountable for tobacco smoking related
diseases.
Despite the potential harm reduction associated with
electronic cigarettes, their use remains controversial and
has raised global debate and public health concerns. Where
some consider electronic cigarettes as a safer alternative to
tobacco smoking, others have viewed electronic cigarettes
as a gateway to tobacco smoking [6,7]. This predicament
has arisen mainly because the use of electronic cigarettes
has evolved far faster than the scientific understanding of
their potential pathophysiological health effects. Although
extensive research over the last 50 years has been con-
ducted to understand the mechanisms by which tobacco
cigarettes lead to cardiovascular and respiratory diseases,
there is a paucity of scientific evidence relating to the
cardiovascular and respiratory health effects of electronic
cigarettes. This was reinforced by Public Health England in
their recent publication in which it was concluded that the
comparative risks of cardiovascular disease and lung dis-
ease have not been quantified, and as such, research
regarding biomarkers of exposure, risk and harm are
required [8].
Rather than waiting several decades for observational
data on the long-term health effects of electronic cigarette
use to become available; pragmatic approaches into inves-
tigating the acute and short-term effects of electronic cig-
arettes, based on the known effects of tobacco smoking,
may provide insights into the health effects of electronic
cigarette. Therefore, in this study we investigated the acute
physiological and biochemical effects following electronic
cigarette use in comparison with tobacco smoking. Param-
eters investigated included: vascular function; respiratory
function; circulating microparticles; platelet microparticles
(PMPs, a biomarker of haemostasis and thrombosis); endo-
thelial microparticles (EMPs, a biomarker of endothelial
function and injury) and levels of circulating soluble adhe-
sion and selectin molecules.
METHODS
Study design
A single-centre prospective randomized cross-over study
was conducted between June 2016 and December 2016.
The study was approved by the University of Glasgow
College of Medical, Veterinary and Life Sciences Research
Ethics Committee (reference number 200150108) and com-
plied with the Declaration of Helsinki. Informed written
consent was obtained from all participants.
Twenty healthy male smokers were sequentially
screened and recruited into the study. Participants were
included if they were men, at least 18 years of age and a
habitual tobacco smoker of one or more tobacco cigarettes
per day. Exclusion criteria included an established history
of cardiovascular, respiratory or renal disease; lack of ability
to provide written consent and history of allergy to any
substance within the e-liquid (nicotine, propylene glycol,
vegetable glycerol, vanillin, furaneol and ethyl vanillin).
Participants were randomly assigned to study arms ‘A’ or ‘B’
in a 1 : 1 ratio. Randomization was conducted by the means
of a secure website (Sealed Envelope) [9]; investigator and
participants were not blinded to the randomization. Ran-
domization determined the order that participants received
each intervention.
All participants attended for two study visits at the same
time of day, with a minimum of 24 h between each visit.
Prior to each study visit participants were asked to fast for a
minimum of 4 h and to refrain from tobacco smoking,
electronic cigarette use and from consuming caffeinated
and alcoholic products for 12 h. Participants were exposed
to each intervention (either tobacco cigarette smoking or
electronic cigarette use) on separate study days. Study
investigations were performed preintervention and post-
intervention (Fig. 1).
Interventions
For the tobacco smoking intervention, participants were
asked to smoke one of their regular tobacco cigarettes.
For the electronic cigarette intervention participants
were asked to use a commercially available second-gener-
ation electronic cigarette device with nicotine-containing e-
liquid. The device consisted of a 1300 mAh variable voltage
rechargeable battery, a tank and an atomizer (SmokeMax;
Groove Trading Ltd, Glasgow, UK). Each tank contained
approximately 1.5 ml of e-liquid. The e-liquid used in the
study was reported by the manufacture to contain 18mg/ml
nicotine, and was tobacco flavoured (Pillbox38 UK Ltd,
Totally Wicked, Blackburn, UK). All the e-liquid used in the
study was manufactured from the same batch.
The e-liquid control of substances hazardous to health
(COSSH) assessment report from the manufacture stated
that the contents per 10ml bottle were: 360-mg nicotine,
12.6-ml propylene glycol, 6.2-ml vegetable glycerine, 120-
mg vanillin, 48mg furaneol and 80-mg ethyl vanillin. An
independent analysis of the e-liquid was performed at the
Nicotine and Tobacco Product Assessment Shared
Resource (NicoTAR), Roswell Park Cancer Institute, Buf-
falo, New York, USA. Nicotine concentrations were deter-
mined using gas chromatography (GC) with a nitrogen–
phosphorus detector (GC–NPD). Flavouring compounds
were also identified in each liquid using a GC/mass spec-
trometry method. The methods for determining the con-
centrations of nicotine and flavouring compounds are
described in previous publications [10–12]. According to
the laboratory report, the average nicotine content was
17.27 mg/ml and the identified flavouring compounds
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correlated closely with the manufactures COSSH report
[refer to table, supplemental digital content (SDC) 1,
http://links.lww.com/HJH/A990].
Each participant was provided with a new electronic
cigarette device, which was prepared by the study inves-
tigator. The investigator filled the tank with e-liquid and
set the battery voltage to 3.3 V. When asked to use the
electronic cigarette participants were asked to take 15
‘puffs’ of the electronic cigarette. This is considered to
be comparable with the amount of nicotine obtained from
smoking a conventional tobacco cigarette, approximately
0.5 mg [13].
FIGURE 1 Study design: 20 healthy male smokers were randomized in a crossover fashion to electronic and tobacco cigarette study arms. Study investigations were
performed before and after each intervention. Washout period between study visits was a minimum of 24 h.
Cardiovascular effects of electronic cigarettes
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Study investigations
All study investigations were performed before and after
each intervention. One trained investigator (D.M.I.K) per-
formed all the investigations.
Assessment of vascular function
Noninvasive blood pressure (BP) measurements were
taken using the auscultatory method on the participant’s
dominant arm using a BP cuff and sphygmomanometer
(Hokanson SC12, Cuff, Hokanson DS400 Aneroid sphyg-
momanometer; DE Hokanson, Inc, Bellevue, Washington,
USA). Three repetitive BP recordings were taken and the
mean SBP and DBP recordings were calculated. Postinter-
vention BP measurements were taken 10min following
the intervention.
Heart rate (HR) was measured immediately before and
1min following the intervention. The radial pulse was
palpated, and the arterial pulse was counted for 60 s.
Reactive hyperaemia index (RHI), a measure of endo-
thelial function via peripheral arterial tonometry (PAT); and
augmentation index, a measure of arterial stiffness, were
assessed using a noninvasive plethysmographic method
(EndoPAT-2000; Itamar Medical Ltd, Caesarea, Israel) in
accordance with the manufactures recommendations. Par-
ticipants were studied in the supine position in a quiet,
temperature controlled room. After a 10-min equilibrium
period a BP cuff was placed on the participant’s nondomi-
nant upper arm (the experimental arm), whereas the con-
tralateral arm served as a control. Pneumatic probes were
fitted to the index fingers of each hand. Baseline pulse wave
amplitude (PWA) was measured for 5min. The BP cuff was
then rapidly inflated on the experimental arm 60mmHg and
SBP (the occlusion pressure did not exceed 200 mmHg) for
a duration of 5min. After exactly 5min of occlusion the BP
cuff was rapidly deflated to induce flow mediated reactive
hyperaemia. A postocclusion recording was then measured
for a further 5min. Postintervention PAT was recorded
15min following the intervention. The PAT data were
automatically analysed using proprietary software (Endo-
PAT-2000; Itamar Medical Ltd) in an operator-independent
manner. RHI was calculated as the ratio of the postocclu-
sion average pulse amplitude to the baseline average pulse
amplitude. The values were normalized to the measure-
ments from the contralateral arm which served as a control
to compensate for nonendothelium dependent systemic
effects. Augmentation index was calculated from PAT
waveform and functioned as a measure of medium and
large arterial wall elasticity. As augmentation index is
related to HR, the augmentation index was corrected to a
standard HR of 75 bpm (AI@75).
Blood sampling
Blood sampling was obtained from 18 of the 20 study
participants. Blood samples were collected from the par-
ticipants’ dominant arm using sodium citrate 3.2% and Z
serum separator clot activator VACUETTE tubes (Greiner
Bio-One Ltd, Stonehouse, Gloucestershire, UK), before and
5min following each intervention. To obtain platelet free
plasma (PFP) the samples were centrifuged at 2000 relative
centrifugal force (RCF) for 10min, the resultant plasma
supernatant was transferred to a clean centrifuge tube
and centrifuged at 1500 RCF for a further 20 min. The serum
samples were obtained by centrifuging whole blood at 2000
RCF for 10min after which the serum was transferred into
storage tubes. All samples were stored at 70 8C until
analysis.
Measurement of serum soluble adhesion and
selectin molecules
Serum samples were thawed then centrifuged at 1000 RCF
at 4 8C for 10min. The molecules were measured using
MILLIPLEX MAP Kit Human Cardiovascular Diseases Mag-
netic Bead Panel 2 (Cat. No HCVD2MAG-67K; Merck Milli-
pore, Feltham, UK) and MILLIPLEX MAP Human
Cardiovascular Disease Panel 4 (Cat. No. HCVD4MAG-
67K; Merck Millipore) in accordance with the manufactures
recommendations. The serum soluble adhesion and selec-
tin molecules quantified were sICAM-1 (soluble intercellu-
lar adhesion molecule 1), sVCAM-1 (soluble vascular
adhesion molecule 1), sE-selectin (endothelial leukocyte
adhesion molecule-1), sP-selectin (soluble platelet selectin)
and PECAM-1 (platelet endothelial cell adhesion molecule).
To qualify the assay performance two quality controls were
performed with each plate. The biomarkers for each sample
were quantified using a MAGPIX instrument (Luminex,
Austin, Texas, USA). The results were then analysed using
the Luminex xPONENT software, version 4.2. Measure-
ments were performed in duplicate and statistical analysis
was performed on the mean values.
Measurement of microparticles
The PFP was thawed and 50ml of PFP was incubated on ice
and in the dark for 30min with 5ml of anti-CD42b-FITC
(1 : 600) (clone HIP1, BD-Pharmingen, San Jose, California,
USA) and 6ml of anti-CD31-APC/Cy7 (1 : 600) (clone WM59,
Biolegend, San Diego, California, USA). Subsequently 2.5ml
of Annexin-V-alexa 647 (Biolegend); 3ml of 0.5 mol/l CaCl2
(aq) (Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK);
and 233.5ml of NaCl (aq) 0.9% was added to make a final
reaction volume of 300ml. FITC-conjugated and APC/Cy7-
conjugated isotype-matched monoclonal antibodies (Biol-
egend) were used for negative controls. Microparticles
were defined as particles identified between 0.1 and
1mm in diameter. Microparticle events were measured
using flow cytometry (FACS Canto II – BD Biosciences)
at constant medium flow for 4 min. The microparticle
events were gated according to size (0.1–1mm) at forward
scatter and side scatter, both in log scale, using 1mm size
beads as a reference (flow cytometry submicron size refer-
ence kit – Molecular Probes, Life Technologies, Thermo
Fisher Scientific, Waltham, Massachusetts, USA). Micropar-
ticles were identified as total microparticles (Annexin Vþ),
PMPs (Annexin Vþ CD31þCD42bþ) and EMPs (Annexin
Vþ CD31þCD42b). The concentrations of microparticles
were calculated using the counting beads (flow cytometry
submicron size reference kit) as a known standard with 1 ml
of PFP used for normalization. FACS data were analysed
using FlowJo software (version 10.0.7; Tree Star, Inc., Ash-
land, Oregon, USA). The absolute number of micropar-
ticles, EMPs and PMPs were calculated using the following
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formula: microparticle/ml¼A (B/C) 20, where A is the
total number of microparticle events observed in the con-
stant flow of 4min; B is the total number of counting beads
added in the FACS tube before acquisition; C is the total
number of beads counted in the constant flow of 4min and
20 is the correction factor for 1ml of plasma. Technical
triplicates were performed for all samples and statistical
analysis was performed on the means.
Assessment of respiratory function
MicroLab spirometer (Micro Medical Limited, Kent, Eng-
land), which complies with both the American Thoracic
Society and European Respiratory Society 2005 standards
were used. Standard spirometry measurements were taken,
including forced expiratory volume in 1 s (FEV1), forced
vital capacity (FVC), FEV1/FVC ratio and peak expiratory
flow (PEF). The machine was calibrated before spirometry
recordings. Height and weight were recorded. All partic-
ipants were asked to take a deep breath (as large as
possible) and blow out as hard and as fast as possible until
there was no air left. Spirometry was repeated a minimum
of three times until the British Thoracic Society quality
criteria was met. The procedure was performed before
and 25min following the intervention. The ‘best’ spirometry
readings were then used for further analysis.
Assessment of exhaled carbon monoxide
Exhaled carbon monoxide was measured using the Bedfont
Microþ Smokerlyzer carbon monoxide monitor (Bedfont
Scientific Ltd, Kent, England) according to the manufactures
recommendations. The Smokerlyser measures carbon mon-
oxide levels in parts per million (ppm) based on the
conversion of carbon monoxide to carbon dioxide over a
catalytically active electrode. A carbon monoxide level
6 ppm or less is considered normal and equates less than
1% of carbon monoxide in blood. Participants were asked
to hold their breath for 15 s before exhaling slowly and fully
into the mouth piece during which the carbon monoxide
was measured. Carbon monoxide levels were recorded
after each breath. Measurements were taken at baseline
and 3min following the intervention.
Statistical analysis
Visual inspection of box-plots and the Shapiro–Wilk test was
applied to assess normality of the data and identify outlier
data points. Parametric andnonparametric testswere used as
appropriate. Continuous variables were expressed as
mean SD or median and 25th–75th percentiles. Compar-
isons of the baseline characteristics between study arms ‘A’
and ‘B’ were made using Student’s t test and Mann–Whitney
U test. Paired Student’s t tests and related samples Wilcoxon
signed rank tests were used to compare continuous variables
between pre and postintervention, as appropriate. A two-
way repeated measures analysis of variance of intervention
(electronic cigarette and tobacco cigarette use) and time
point relative to intervention (preintervention and postin-
tervention) was also performed, relating to all dependant
variables (refer to table, SDC 2, http://links.lww.com/HJH/
A990). Statistical significance was set at 0.05 and analyses
were conducted using SPSS statistical software (IBM SPSS
Statistics, version 24.0; IBM Corp, Armonk, New York, USA)
and GraphPad Prism, version 7.00 for Mac OS X (GraphPad
Software, La Jolla, California, USA, www.graphpad.com).
RESULTS
Study cohort
Baseline characteristics are summarized in Table 1. All
participants (mean age 31.6 10.5 years) were regular
tobacco smokers and consumed an average of seven
tobacco cigarettes per day. Statistical analysis demonstrated
that these characteristics were similar for participants who
had been randomized to either study arm A or B. There was
heterogeneity in the brand of tobacco cigarettes used; all
were commercially available cigarettes. In total, there were
six different brands (refer to table, SDC 3, http://link-
s.lww.com/HJH/A990).
Cardiovascular function
Table 2 summarizes the cardiovascular and circulating
microparticles changes following the use of both interven-
tions. One minute following the use of both an electronic
cigarette and tobacco cigarette, HR significantly increased
(Fig. 2a). However, tobacco smoking elicited a significantly
greater increase in HR (15 12 bpm; P< 0.001) in compar-
ison with the increase following electronic cigarette use
(refer to table, SDC 4, http://links.lww.com/HJH/A990).
Although no statistical difference was observed in either
SBP or DBP following the use of an electronic or tobacco
cigarette in comparison with the baseline parameters, the
changes in SBP were greater following tobacco cigarette
use (4 9mmHg) compared with electronic cigarette use
(1 6mmHg) (P¼ 0.046) (refer to table, SDC 4, http://
links.lww.com/HJH/A990).
A statistically significant increase in RHI (P¼ 0.006) and
an increase in augmentation index (P¼ 0.010) were seen
immediately after using an electronic cigarette. Changes in
TABLE 1. Baseline characteristics
Characteristics All, n¼20
Age (years) 31.610.5a
BMI (kg/m2) 25.75a
Smoking duration (years) 13 (722)b
Number of tobacco cigarettes smoked (per day) 7 (130)c
Number of days between study visits 6 (113)b
SBP (mmHg) 12313a
DBP (mmHg) 7910a
HR (bpm) 649a
RHI 1.910.41a
PWA occluded arm (AU) 833387a
PWA control arm (AU) 871423a
AI (%) 8.210.9a
AI@75 15.012.1a
CO (ppm) 5 (211)b
FEV1 (l) 4.20.6a
FVC (l) 5.3 (4.95.8)b
FEV1/FVC (%) 81.56.9a
PEF (l/min) 57066a
Data are presented as mean SDa, median (25th75th percentiles)b or mode (range)c.
AI, augmentation index; AI@75, augmentation index at heart rate of 75bpm; AU,
arbitrary units; CO, exhaled carbon monoxide; FEV1, forced expiratory volume in 1 s;
FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity ratio; PEF, peak expiratory
flow; PWA, pulse wave amplitude; RHI, reactive hyperaemia index.
Cardiovascular effects of electronic cigarettes
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these parameters were not statistically significant after using
a tobacco cigarette (P> 0.05) (Fig. 2c). When the changes in
augmentation index were compared between electronic
cigarettes and tobacco cigarettes pre and postintervention,
there were statistically significant differences between the
interventions (5.6 8.0%, P¼ 0.006) (Figs. 2b and 3a and
SDC 4, http://links.lww.com/HJH/A990). However, when
the augmentation index was standardized to a HR of
75 bpm no significant difference was seen following either
electronic or tobacco cigarette use or between interventions
(all P> 0.05).
Exposure to electronic cigarettes and tobacco cigarettes
led to a significant reduction in PWA in both the occluded
arm (both interventions P< 0.001) and the control arm
(electronic cigarette P¼ 0.001, tobacco cigarette P< 0.001)
(Fig. 3b and c).
Levels of circulating soluble adhesion and
selectin molecules
The serum concentrations of sP-selectin decreased follow-
ing electronic cigarette exposure (P¼ 0.026). However, no
significant changes in the concentrations of sP-selectin
were seen following tobacco cigarette exposure
(P> 0.05). Conversely, serum concentrations of PECAM-1
decreased following tobacco cigarette use (P¼ 0.028),
whereas no significant changes in the concentration of
PECAM-1 levels were demonstrated following electronic
cigarette use (P> 0.05). No significant changes were
detected in the serum concentrations of sICAM-1,
sVCAM-1, sE-selectin following either interventions (all
P> 0.05).
Circulating microparticles
Five minutes following tobacco cigarette use, the total
number of circulating microparticles, EMPs and PMPs all
significantly increased following tobacco cigarette use
(P< 0.001). In contrast, only PMPs increased following
electronic cigarette use (P< 0.001), whereas there were
no significant changes in either the total number of micro-
particles or EMPs detected 5min following electronic ciga-
rette use (P> 0.05) (Fig. 4).
Respiratory function and exhaled carbon
monoxide levels
Table 3 summarizes the changes observed in the respiratory
function and carbon monoxide level at baseline and fol-
lowing the use of both interventions. No statistically signifi-
cant change was seen for FEV1, FVC or FEV1/FVC following
TABLE 2. Cardiovascular parameters and circulating biomarkers of vascular function at baseline and following electronic cigarette and
tobacco cigarette use
Parameter Intervention Preintervention Postintervention Change following intervention P value
HR (bpm) Electronic cigarette 659 738 85 <0.001b
Tobacco cigarette 648 8613 2312 <0.001b
SBP (mmHg) Electronic cigarette 12412 12311 16 0.431a
Tobacco cigarette 12114 12514 49 0.058a
DBP (mmHg) Electronic cigarette 8011 8010 05 0.950b
Tobacco cigarette 7511 7710 25 0.167b
RHI Electronic cigarette 1.680.33 1.960.44 0.280.38 0.006b
Tobacco cigarette 1.860.47 1.960.51 0.100.44 0.156b
PWA occluded arm (AU) Electronic cigarette 860397 465359 395310 <0.001b
Tobacco cigarette 895392 437387 458324 <0.001b
PWA control arm (AU) Electronic cigarette 906434 507399 399353 0.001b
Tobacco cigarette 966451 475396 492340 <0.001b
AI (%) Electronic cigarette 10.513.2 6.913.5 3.75.7 0.010a
Tobacco cigarette 9.010.0 10.913.5 1.97.4 0.265a
AI@75 (%) Electronic cigarette 16.614.5 14.314.6 2.36.5 0.131a
Tobacco cigarette 15.610.4 16.213.9 0.77.8 0.709a
sICAM-1 (ng/ml) Electronic cigarette 42.0 (21; 60) 35.0 (24.3; 62.3) 4.0 (9.0; 5.3) 0.381b
Tobacco cigarette 46.0 (17.8; 54.8) 42.0 (25.0; 57.0) 1.5 (4.3; 4.5) 0.868b
sP-selectin (ng/ml) Electronic cigarette 95.0 (70.8; 125.3) 84.0 (60.5; 107.5) 19.5 (33.0; 5.5) 0.026b
Tobacco cigarette 87.0 (65.8; 116.5) 79.0 (57.0; 97.0) 12.5 (19.0; 9.0) 0.117b
sVCAM-1 (ng/ml) Electronic cigarette 713.0 (617.3; 841.0) 722.0 (609.0; 788.0) 25.0 (85.3; 73.3) 0.349b
Tobacco cigarette 698.0 (585.8; 797.3) 710.5 (613.5; 826.5) 3.0 (50.3; 78.3) 0.647b
sE-selectin (ng/ml) Electronic cigarette 65.5 (48.4; 108.1) 63.4 (55.4; 101.1) 0.9 (3.2; 5.8) 0.948b
Tobacco cigarette 71.8 (50.7; 109.6) 64.4 (40.2; 108.2) 0.8 (6.6; 2.6) 0.372b
PECAM-1 (ng/ml) Electronic cigarette 0.95 (0.83; 1.04) 0.91 (0.79; 1.20) 0.04 (0.07; 0.05) 0.554b
Tobacco cigarette 1.04 (0.83; 1.28) 0.93 (0.74; 1.27) 0.06 (0.12; 0.00) 0.028b
log10 MPs/ml Electronic cigarette 5.7 (5.3; 6.1) 5.8 (5.2; 6.1) 0.2 (0.5; 0.7) 0.766b
Tobacco cigarette 5.7 (5.5; 6.2) 6.3 (5.9; 6.9) 0.4 (0.2; 1.1) <0.001b
log10 EMPs/ml Electronic cigarette 4.8 (4.3; 5.3) 4.9 (4.3; 5.5) 0.0 (0.5; 0.7) 0.966b
Tobacco cigarette 4.9 (4.1; 5.5) 5.5 (5.2; 6.3) 0.6 (0.3; 1.6) <0.001b
log10 PMPs/ml Electronic cigarette 5.0 (4.2; 5.7) 6.2 (5.7; 6.8) 1.4 (0.6; 1.8) <0.001
b
Tobacco cigarette 4.8 (4.4; 5.6) 6.0 (5.7; 7.1) 1.0 (0.3; 2.1) <0.001b
Remaining abbreviations are as reported in previous tables. Data are presented as mean SD and median (25th75th percentiles). P values derived from paired t testa and related-
samples Wilcoxon signed ranked testb. EMPs, endothelial microparticles; MPs, microparticles; PECAM-1, platelet endothelial cell adhesion molecule; PMPs, platelet microparticles; sE-
selectin, endothelial leukocyte adhesion molecule-1; sICAM-1, soluble intercellular adhesion molecule 1; sP-selectin, soluble platelet selectin; sVCAM-1, soluble vascular adhesion
molecule 1.
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either the use of an electronic or a tobacco cigarette. PEF
significantly decreased following the use of an electronic
cigarette (P¼ 0.019) but not following the use of a tobacco
cigarette (P> 0.05). Carbon monoxide increased following
tobacco cigarette use (P< 0.001), whereas an overall reduc-
tion in exhaled carbon monoxide levels was seen following
electronic cigarette use (P¼ 0.007).
DISCUSSION
In this cross-over randomized study in 20 healthy male
smokers, we explored the immediate effects of electronic
cigarettes and tobacco cigarettes on endothelial function,
arterial stiffness, cardiovascular haemodynamic parame-
ters, pulmonary function and circulating microparticles.
FIGURE 2 Comparison of changes in heart rate and augmentation index parameters before and after electronic and tobacco cigarette use. (a) Heart rate; (b) augmentation
index; (c) augmentation index at heart rate of 75 bpm.
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We observed a significant increase in HR following the
use of both interventions, the effect was more pronounced
following exposure to tobacco smoking. This haemody-
namic response was expected as nicotine is known to
activate the sympathetic nervous system, resulting in a
transient rise in HR, BP and systemic vasoconstriction
[14]. This is supported by a previous study by Grassi
et al. [15] which demonstrated significant increases in
HR, SBP and DBP which were accompanied by increases
in plasma noradrenaline and adrenaline levels. In our study,
the significantly greater rise in HR following tobacco ciga-
rette use, compared with electronic cigarette use, may be
explained by a faster nicotine absorption rate from tobacco
cigarettes in comparison with electronic cigarettes [16–18].
FIGURE 3 Comparison of changes in vascular function parameters before and after electronic and tobacco cigarette use. (a) Reactive hyperaemia index; (b) Control arm
baseline pulse wave amplitude; (c) occluded arm baseline pulse wave amplitude.
Kerr et al.
8 www.jhypertension.com Volume 36  Number 1  Month 2018
CE: Swati; JH-D-17-00950; Total nos of Pages: 13;
JH-D-17-00950
Reports on the BP effects in other acute exposure studies
comparing electronic cigarette to tobacco cigarettes studies
are inconsistent [19–21]. In our study, we did not observe
any significant changes in SBP or DBP following tobacco
cigarette exposure or electronic cigarette exposure. Differ-
ences between our results and previously reported data by
Grassi et al. [15], may be due to differences in the tobacco
cigarettes used and in assessment of BP. Different levels of
nicotine exposure will impact on the levels of catechol-
amines and subsequently affect the pressor response. In our
study, participants smoked one of their own tobacco cig-
arettes and the nicotine content of each tobacco cigarette
FIGURE 4 Comparison of changes in circulating microparticles, microparticles before and after electronic cigarette use. (a) Total microparticles; (b) endothelial micro-
particles; (b) platelet microparticles.
Cardiovascular effects of electronic cigarettes
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was unknown; BP was measured at a single time point
(10 min following exposure). In contrast, in the study by
Grassi et al. findings were derived from continuous hae-
modynamic measurements for 15min following exposure
to a standardized tobacco cigarette containing 1.1-
mg nicotine.
We observed an acute increase in augmentation index
following electronic cigarette use. However, when we
corrected augmentation index for HR [22], we found no
significant differences in AI@75, suggesting that effects on
augmentation index are due to changes in HR rather than
acute changes in vascular stiffness. As previously men-
tioned, this difference in HR could be explained by the
difference in the efficiency of the nicotine delivery systems
between electronic and tobacco cigarettes [16–18]. Con-
versely to our findings, Vlachopoulos et al. recently pub-
lished a study using carotid–femoral pulse wave velocity as
a direct method to study aortic stiffness in 24 healthy
habitual smokers. They demonstrated that pulse wave
velocity increased 5 min following the use of a tobacco
cigarette and an electronic cigarette [23]. Given the fact that
aortic stiffness is known to be an independent predictor of
cardiovascular risk [24] further long-term studies are war-
ranted to explore the potential impact of electronic ciga-
rettes on aortic stiffness.
In our study, RHI increased following the use of an
electronic cigarette. The mean RHI response following
tobacco smoking demonstrated an increase; however, this
failed to reach statistical significance. In contrast, the base-
line PWAs (recorded prior to cuff occlusion during PAT
measurements before and after each intervention) were
significantly reduced following both interventions.
Although a decrease in RHI was not demonstrated, the
changes in PWA, suggestive of an acute vasoconstrictive
response following nicotine exposure, may provide an
explanation for this. A vessel in its constricted state has
greater capacity to vasodilate relative to its preconstricted
state. The inverse of this phenomenon has been reported in
pregnancy in which the RHI response paradoxically sug-
gested a deterioration in endothelial function. However, in
keeping with the vasodilatory response in pregnancy, the
baseline PWA was significantly increased, suggesting that in
the later stages of pregnancy the vasculature was less able
to vasodilate as it had already reached its vasodilatory
capacity [25]. Furthermore, it would be counter-intuitive
if an improvement was seen in endothelial function follow-
ing either product. Mechanistically the exposure of endo-
thelial cells to tobacco smoke is known to increase the
production of superoxide and reactive oxide species. This
leads to oxidative stress along with uncoupling of endothe-
lial nitric oxide synthase. Uncoupling of endothelial nitric
oxide synthase decreases the bioavailability of nitric oxide
which results in impaired endothelium dependent vasodi-
lation. Carnevale et al. [26] demonstrated in 40 healthy
individuals (20 smokers and 20 nonsmokers) deterioration
in markers of oxidative stress and flow mediated dilation
(FMD) 30min following a single exposure to either elec-
tronic cigarettes or tobacco cigarettes. Furthermore, their
findings question whether FMD is a more optimal tech-
nique over PAT to assess the endothelial response follow-
ing acute exposure to both electronic and tobacco
cigarette research.
It is known that proinflammatory stimuli including
tobacco smoking, can stimulate the expression of adhesion
molecules (ICAM-1, VCAM-1 and E-selectin) on the surface
of vascular endothelial cells [27–30], suggesting that ele-
vated levels of soluble adhesion molecules may serve as a
surrogate markers to detect preclinical endothelial dysfunc-
tion [31,32]. Therefore, as an adjunct to assessment of
endothelium-dependent vasodilation, we measured con-
centrations of serum soluble adhesion and selectin mole-
cules. In our study, serum concentrations of these
molecules did not demonstrate any consistent pattern of
activation following both electronic and tobacco cigarette
exposure. In this context, however, it is important to note
that there is controversy about the utility of these markers to
act as a surrogate of endothelium-dependent vasodilation
[33].
For the cardiovascular risk of electronic cigarettes to be
estimated, data from longitudinal observational studies
need to emerge. As it may take several decades for the
cardiovascular impact from long-term electronic cigarette
exposure to be fully understood, biomarkers of cardiovas-
cular disease may have a role in assessing the probability of
whether electronic cigarette exposure is likely to be asso-
ciated with cardiovascular disease. Therefore, biomarker
studies may have an important role in developing an
understanding of any potential cardiovascular risks associ-
ated with long-term electronic cigarette use. Improvements
in the understanding of the relationship between electronic
TABLE 3. Respiratory physiological parameters at baseline and following electronic cigarette and tobacco cigarette use
Parameter Intervention Preintervention Postintervention Change following intervention P value
FEV1 (l) Electronic cigarette 4.20.6 4.10.7 0.10.2 0.132a
Tobacco cigarette 4.30.7 4.20.6 0.00.2 0.373a
FVC (l) Electronic cigarette 5.20.7 5.10.7 0.10.3 0.433b
Tobacco cigarette 5.30.9 5.20.8 0.00.3 0.723b
FEV1/FVC (%) Electronic cigarette 81.16.8 80.97.3 0.22.0 0.629b
Tobacco cigarette 81.37.0 81.07.2 0.34.8 0.501b
PEF (l/min) Electronic cigarette 56262 53196 3154 0.019a
Tobacco cigarette 56772 54581 2253 0.074a
CO (ppm) Electronic cigarette 910 77 23 0.007b
Tobacco cigarette 910 2010 112 <0.001b
Data are presented as mean SD. P values derived from paired t testa and related-samples Wilcoxon signed ranked testb. FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity
ratio; PEF, peak expiratory flow; CO, carbon monoxide.
Kerr et al.
10 www.jhypertension.com Volume 36  Number 1  Month 2018
CE: Swati; JH-D-17-00950; Total nos of Pages: 13;
JH-D-17-00950
cigarettes and the cardiovascular system will enable health-
care professionals and individuals to make more informed
health decisions regarding the use of electronic cigarettes.
Microparticles are emerging as a possible biomarker for
early detection of endothelial dysfunction, vascular inflam-
mation and thrombotic state [34]. Microparticles are defined
as membrane-bound vesicles which are between 0.1 and
1mm in diameter; which are formed from the outward
blebbing and shedding of the plasma membrane of cells
undergoing activation, stress or apoptosis [35]. Micropar-
ticles are released from several cell types including leuko-
cytes, erythrocytes, endothelial cells and platelets.
Our study demonstrates that the number of EMPs and
PMPs significantly increased following exposure from
smoking a single tobacco cigarette. We also observed a
comparable significant increase in numbers of PMPs fol-
lowing electronic cigarette exposure. However, no signifi-
cant rise in EMPs was detected following electronic
cigarette use. Mobarrez et al. [36] conducted a study that
focused on acute exposure of healthy volunteers to a single
tobacco cigarette and identified a significant acute release
of EMPs and PMPs. When they repeated the same study
design but substituted tobacco cigarettes for electronic
cigarettes they identified that E-selectin positive micropar-
ticles of endothelial origin were the only microparticle
elevated (P¼ 0.038) [37]. As the relationship between elec-
tronic cigarette exposure and atherosclerotic disease
remain largely unknown it is important to consider the
potential significance of our data in which both tobacco and
electronic cigarette exposure were associated with a signif-
icant increase in numbers of PMPs. In-vivo studies have
demonstrated increased levels of PMPs in those with coro-
nary heart disease [38]. It is suggested increased PMPs may
have a role in the thrombotic and atherogenic processes
leading to cardiovascular events [39]. Numerous studies
have demonstrated that increased EMP levels correlate with
impaired FMD and arterial stiffness [40,41] and are consid-
ered independent predictors of cardiovascular events [42].
Therefore, even though our data did not detect any signifi-
cant changes in EMPs or deterioration in endothelial func-
tion following electronic cigarette exposure, the positive
findings presented in the studies by Antoniewicz et al. [37]
and Carnevale et al. [26], need to be considered and further
research is required to explore this phenomena in
more detail.
From a respiratory perspective, we did not observe any
significant changes relating to FEV1, FVC and FEV1/FVC.
However, we did observe an immediate reduction in PEF
following the electronic cigarette use, which was not seen
following the use of a tobacco cigarette. This may be
suggestive of a defensive physiological response against
the irritants from the electronic cigarette aerosol. Elec-
tronic cigarette users report that this irritative psychoso-
matic effects (also referred to as ‘throat hit’) are associated
with an increased perception of efficacy as it replicates
the sensation associated with tobacco cigarette use [43].
This effect may be secondary to e-liquid solvent propyl-
ene glycol (1,2 propanediol), which when inhaled is
known to cause throat airway irritation [44]. However,
there is no evidence to date to suggest that such an
irritation from propylene glycol could potentiate into a
clinically significant adverse acute or short-term
respiratory effects.
Study limitations
Our study has several limitations which should be acknowl-
edged. Prior to this study being conducted there were no
similar studies available to allow sample size and power
calculations. Therefore, a convenience sample of 20 par-
ticipants and the cross-over design appeared appropriate
for this exploratory study. All study participants were men
and were restricted to using only one specific electronic
cigarette device and e-liquid. Therefore, our data cannot be
generalized to the wider population, and are not necessarily
applicable to the use of different e-liquids and electronic
cigarettes which are available.
We relied on participant self-reporting to confirm absti-
nence from tobacco smoking, electronic cigarette use and
ingestion of caffeinated and alcoholic products prior to the
study investigation. As we were unable to control the study
participants’ behaviour out-with the study environment, we
acknowledge that the self-reporting accounts are vulnera-
ble to misrecollection [45]. The average carbon monoxide
data at baseline provides some reassurance that there was
no tobacco cigarette use immediately prior to the study
visits.
In our study, blood sampling was performed at baseline
and 5min following exposure to electronic cigarettes or
tobacco cigarettes. As serial blood sampling was not per-
formed we are naı¨ve as to trajectory and timings relating to
peak values of circulating microparticles, levels of serum
soluble adhesion and selectin molecules and the differ-
ences between electronic and tobacco cigarette exposure.
This point is further illustrated by the previously discussed
acute exposure studies conducted by Mobarrez et al. [36]
and Antoniewicz et al. [37]. In both studies, which per-
formed serial blood sampling at 1, 2, 4 and 24 h following
tobacco cigarette or electronic cigarette exposure, the time
of peak detection of PMPs and EMPs differed between
interventions.
It is likely that participants will have been exposed to
variable amounts of nicotine, as participants in the study
used their own brand of tobacco cigarettes, and exhibited
different smoking and vaping techniques. Although plasma
nicotine levels were not measured, the physiological
changes seen in HR are consistent with the haemodynamic
responses that have been reported and validated in other
studies, demonstrating that tobacco cigarettes deliver nico-
tine at a faster rate than electronic cigarettes [16,18].
On a more general note, our study has been designed
around restrictions that apply to cigarette smoking in the
United Kingdom where there is a smoking ban on all
National Health Service premises which includes our Clini-
cal Research Facility. As such we had to conduct this project
in a dedicated facility in our research centre where smoking
outside the building is permitted. This still required moving
participants from exposure outdoors to assessment indoors
and caused slight delay between exposure and haemody-
namic assessment and blood sampling. We have therefore
limited our studies to parameters that can be assessed
relatively quickly and have selected a limited range of
vascular function tests for this project to keep the delay
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between exposure and assessment as short as possible. We
are aware that a more comprehensive set of data would add
further value to our study and indeed collect such data
currently in an ongoing longer term exposure study.
In conclusion, to our knowledge this is the first reported
study to use PAT to assess the endothelial function response
following the use of electronic cigarettes with comparison
with tobacco cigarettes. We have postulated that the RHI
response may have arisen following the vasoconstrictive
response to nicotine. This is an important methodological
consideration for future researchers in this field. Further-
more, we have demonstrated that both electronic and
tobacco cigarettes elicit differential effects on circulating
microparticles. Our findings suggest that electronic ciga-
rette use induces vasoreactivity and that tobacco cigarette
use causes an endothelial inflammatory response. Under-
lying mechanisms for these differential responses are
unclear but should be investigated. With regards to elec-
tronic cigarettes, the long-term effects of these phenomena
and their potential association with atherogenesis and
cardiovascular risk await further clarification.
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